Werewolf Therapeutics (HOWL) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings or view top-rated stocks.

2 equities research analysts have issued twelve-month price objectives for Werewolf Therapeutics' stock. Their HOWL share price forecasts range from $8.30 to $15.00. On average, they anticipate the company's stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 290.8% from the stock's current price.
View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts.

Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 38.5% and is now trading at $2.84.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HOWL earnings forecast.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 241.79% and a negative trailing twelve-month return on equity of 40.02%.

(HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL."

Werewolf Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (5.45%), Alyeska Investment Group L.P. (1.12%), Acadian Asset Management LLC (0.22%), Schonfeld Strategic Advisors LLC (0.21%), HBK Sorce Advisory LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends.

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HOWL stock can currently be purchased for approximately $2.84.

Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $101.13 million and generates $16.40 million in revenue each year. The company earns $-53,810,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis.

Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com.